Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, discusses updated overall survival results on cabozantinib vs sunitinib as initial targeted treatment for patients with metastatic renal cell carcinoma (Abstract LBA38).
Jaafar Bennouna, MD, of the University of Nantes, discusses findings from a phase II French study of bevacizumab or cetuximab plus chemotherapy after progression with bevacizumab plus chemotherapy in patients with wild-type KRAS metastatic colorectal cancer (Abstract 477O).
Bonnie S. Glisson, MD, of The University of Texas MD Anderson Cancer Center, discusses a clinical trial on the combination of ISA101, an HPV-16 vaccine, and nivolumab for patients with incurable HPV-16+ cancer (Abstract 1136O).
Mansoor Mirza, MD, of Copenhagen University Hospital, discusses quality of life in patients with recurrent ovarian cancer treated with niraparib (Abstract 930O).
Robert A. Figlin, MD, of Cedars-Sinai Medical Center, discusses an interim analysis of phase III findings on rocapuldencel-T, an individualized immunotherapy, for newly diagnosed patients with metastatic renal cell carcinoma (Abstract 1137O).
Michèle Beau-Faller, MD, PhD, of the Hôpital de Hautepierre & Institut Régional du Cancer, discusses study results on ultrasensitive detection of EGFR T790M mutation by droplet digital PCR in TKI naïve non–small cell lung cancer harboring EGFR mutation (Abstract 85PD).
